This false-positive genotyping result would mistakenly predict the CYP2C19 metabolizer phenotype of an individual as an intermediate metabolizer (IM), which may increase the predicted risk for major adverse cardiovascular events (e.g., cardiovascular death, myocardial infarction, stroke, and stent thrombosis) in acute coronary syndromes/PCI patients treated with clopidogrel. This evidence concerns the gene CYP2C19 and stroke disorder.